DexCom, Inc. (DXCM)
Cwm LLC Sells 91,609 Shares of DexCom, Inc. $DXCM
Cwm LLC reduced its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 57.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,380 shares of the medical device company's stock after selling 91,609 shares during the quarter. Cwm LLC's holdings in DexCom
A Look at DexCom Inc (DXCM) After 3.1% Decline -- GF Value $109.23 vs Price $62.60
On April 21, 2026, DexCom Inc (DXCM) shares fell 3.1%, bringing the current price to $62.60. The stock has experienced a challenging year, with a 52-week range
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.
DexCom (DXCM) Upgraded to Buy: Here's Why
DexCom (DXCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cinctive Capital Management LP Takes $4.45 Million Position in DexCom, Inc. $DXCM
Cinctive Capital Management LP purchased a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 66,148 shares of the medical device company's stock, valued at approximately $4,451,000. A number of other institutional investors have also added to
Bamco Inc. NY Reduces Stock Position in DexCom, Inc. $DXCM
Bamco Inc. NY decreased its holdings in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,500 shares of the medical device company's stock after selling 60,000 shares during the period. Bamco Inc. NY
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further
Dexcom has been outperforming its peers since our last coverage in December. I expect further progress this year, as the company's long-suffering gross margin profile is set to reverse course over the next fewyears with +200bps of improvements expected this year alone. DXCM's earnings multiple is pricier than other medical equipment peers, but if the degree of medium term earnings growth is taken into consideration, its valuations look cheap.
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
